Show simple item record

dc.contributor.authorSandø-Klemmetvoll, Alina Desiree
dc.contributor.authorFougner, Reidun
dc.contributor.authorRøyset, Elin Synnøve
dc.contributor.authorDai, Hong Yan
dc.contributor.authorGrønbech, Jon Erik
dc.contributor.authorBringeland, Erling Audun
dc.date.accessioned2023-11-10T09:54:21Z
dc.date.available2023-11-10T09:54:21Z
dc.date.created2023-05-12T13:43:57Z
dc.date.issued2023
dc.identifier.citationCancers. 2023, 5(8), 2318en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11250/3101819
dc.description.abstractBackground: The method of response evaluation following neoadjuvant chemotherapy (NAC) in resectable gastric cancer has been widely debated. An essential prerequisite is the ability to stratify patients into subsets of different long-term survival rates based on the response mode. Histopathological measures of regression have their limitations, and interest resides in CT-based methods that can be used in everyday settings. Methods: We conducted a population-based study (2007–2016) on 171 consecutive patients with gastric adenocarcinoma who were receiving NAC. Two methods of response evaluation were investigated: a strict radiological procedure using RECIST (downsizing), and a composite radiological/pathological procedure comparing the initial radiological TNM stage to the pathological ypTNM stage (downstaging). Clinicopathological variables that could predict the response were searched for, and correlations between the response mode and long-term survival rates were assessed. Results: RECIST failed to identify half of the patients progressing to metastatic disease, and it was unable to assign patients to subsets with different long-term survival rates based on the response mode. However, the TNM stage response mode did achieve this objective. Following re-staging, 48% (78/164) were downstaged, 15% (25/164) had an unchanged stage, and 37% (61/164) were upstaged. A total of 9% (15/164) showed a histopathological complete response. The 5-year overall survival rate was 65.3% (95% CI 54.7–75.9%) for TNM downstaged cases, 40.0% (95% CI 20.8–59.2%) for stable disease, and 14.8% (95% CI 6.0–23.6%) for patients with TNM progression, p < 0.001. In a multivariable ordinal regression model, the Lauren classification and tumor site were the only significant determinants of the response mode. Conclusions: Downsizing, as a method for evaluating the response to NAC in gastric cancer, is discouraged. TNM re-staging by comparing the baseline radiological CT stage to the pathological stage following NAC is suggested as a useful method that may be used in everyday situations.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleResponse Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Canceren_US
dc.title.alternativeResponse Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.volume15en_US
dc.source.journalCancersen_US
dc.source.issue8en_US
dc.identifier.doi10.3390/cancers15082318
dc.identifier.cristin2147175
dc.source.articlenumber2318en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal